Literature DB >> 22614326

The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.

Jeannine Skinner1, Janessa O Carvalho, Guy G Potter, April Thames, Elizabeth Zelinski, Paul K Crane, Laura E Gibbons.   

Abstract

BACKGROUND: The Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog) is widely used in AD, but may be less responsive to change when used in people with mild cognitive impairment (MCI).
METHODS: Participants from the Alzheimer's Disease Neuroimaging Initiative were administered a neuropsychological battery and 1.5 T MRI scans over 2-3 years. Informants were queried regarding functional impairments. Some participants had lumbar punctures to obtain cerebrospinal fluid (CSF). We added executive functioning (EF) and functional ability (FA) items to the ADAS-Cog to generate candidate augmented measures. We calibrated these candidates using baseline data (n = 811) and selected the best candidate that added EF items alone and that added EF and FA items. We selected candidates based on their responsiveness over three years in a training sample of participants with MCI (n = 160). We compared traditional ADAS-Cog scores with the two candidates based on their responsiveness in a validation sample of participants with MCI (n = 234), ability to predict conversion to dementia (n = 394), strength of association with baseline MRI (n = 394) and CSF biomarkers (n = 193).
RESULTS: The selected EF candidate added category fluency (ADAS Plus EF), and the selected EF and FA candidate added category fluency, Digit Symbol, Trail Making, and five items from the Functional Assessment Questionnaire (ADAS Plus EF&FA). The ADAS Plus EF& FA performed as well as or better than traditional ADAS-Cog scores.
CONCLUSION: Adding EF and FA items to the ADAS-Cog may improve responsiveness among people with MCI without impairing validity.

Entities:  

Mesh:

Year:  2012        PMID: 22614326      PMCID: PMC3873823          DOI: 10.1007/s11682-012-9166-3

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.978


  36 in total

1.  Tests of executive function predict instrumental activities of daily living in community-dwelling older individuals.

Authors:  Deborah A Cahn-Weiner; Patricia A Boyle; Paul F Malloy
Journal:  Appl Neuropsychol       Date:  2002

2.  Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Authors:  Mary Sano; Rema Raman; Jennifer Emond; Ronald G Thomas; Ronald Petersen; Lon S Schneider; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

3.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

4.  Selectivity of executive function deficits in mild cognitive impairment.

Authors:  Jason Brandt; Eleni Aretouli; Eleanor Neijstrom; Jaclyn Samek; Kevin Manning; Marilyn S Albert; Karen Bandeen-Roche
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

5.  Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease.

Authors:  Patrick J Brown; D P Devanand; Xinhua Liu; Elise Caccappolo
Journal:  Arch Gen Psychiatry       Date:  2011-06

6.  Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.

Authors:  Daniel A Llano; Genevieve Laforet; Viswanath Devanarayan
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

7.  The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment.

Authors:  Marwan N Sabbagh; Michael Malek-Ahmadi; Rahul Kataria; Christine M Belden; Donald J Connor; Caleb Pearson; Sandra Jacobson; Kathryn Davis; Roy Yaari; Upinder Singh
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.

Authors:  Ralf Ihl; Steven Ferris; Philippe Robert; Bengt Winblad; Serge Gauthier; Frank Tennigkeit
Journal:  Int J Geriatr Psychiatry       Date:  2011-03-08       Impact factor: 3.485

9.  Combined memory and executive function tests can screen mild cognitive impairment and converters to dementia in a community: the Osaki-Tajiri project.

Authors:  Eriko Nakata; Mari Kasai; Masashi Kasuya; Kyoko Akanuma; Mitsue Meguro; Hiroshi Ishii; Satoshi Yamaguchi; Kenichi Meguro
Journal:  Neuroepidemiology       Date:  2009-05-30       Impact factor: 3.282

10.  Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations.

Authors:  Matthew C Evans; Josephine Barnes; Casper Nielsen; Lois G Kim; Shona L Clegg; Melanie Blair; Kelvin K Leung; Abdel Douiri; Richard G Boyes; Sebastien Ourselin; Nick C Fox
Journal:  Eur Radiol       Date:  2009-09-16       Impact factor: 5.315

View more
  45 in total

Review 1.  A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.

Authors:  Jacob S Buckley; Shelley R Salpeter
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

2.  A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual.

Authors:  Magda Bucholc; Xuemei Ding; Haiying Wang; David H Glass; Hui Wang; Girijesh Prasad; Liam P Maguire; Anthony J Bjourson; Paula L McClean; Stephen Todd; David P Finn; KongFatt Wong-Lin
Journal:  Expert Syst Appl       Date:  2019-04-10       Impact factor: 6.954

3.  Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Authors:  Michael Ewers; Nicolai Franzmeier; Marc Suárez-Calvet; Estrella Morenas-Rodriguez; Miguel Angel Araque Caballero; Gernot Kleinberger; Laura Piccio; Carlos Cruchaga; Yuetiva Deming; Martin Dichgans; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; Christian Haass
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

4.  An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).

Authors:  N Maritza Dowling; Daniel M Bolt; Sien Deng
Journal:  Psychol Assess       Date:  2016-01-25

5.  A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).

Authors:  A M Wessels; E R Siemers; P Yu; S W Andersen; K C Holdridge; J R Sims; K Sundell; Y Stern; D M Rentz; B Dubois; R W Jones; J Cummings; P S Aisen
Journal:  J Prev Alzheimers Dis       Date:  2015-12-01

6.  Dementia-Related Neuropsychological Testing Considerations in Non-Hispanic White and Latino/Hispanic Populations.

Authors:  Shanna L Burke; Mitra Naseh; Miriam J Rodriguez; Aaron Burgess; David Loewenstein
Journal:  Psychol Neurosci       Date:  2019-03-11

Review 7.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

8.  Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.

Authors:  José A Luchsinger; Thania Perez; Helena Chang; Pankaj Mehta; Jason Steffener; Gnanavalli Pradabhan; Masanori Ichise; Jennifer Manly; Davangere P Devanand; Emilia Bagiella
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

9.  Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Authors:  Holly Posner; Rosie Curiel; Chris Edgar; Suzanne Hendrix; Enchi Liu; David A Loewenstein; Glenn Morrison; Leslie Shinobu; Keith Wesnes; Philip D Harvey
Journal:  Innov Clin Neurosci       Date:  2017-02-01

10.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.